Stock Scorecard
Stock Summary for Amylyx Pharmaceuticals Inc (AMLX) - $13.29 as of 6/3/2026 11:55:31 AM EST
Total Score
13 out of 30
Safety Score
31 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AMLX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AMLX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AMLX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AMLX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AMLX (31 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AMLX
Financial Details for AMLX
Company Overview |
|
|---|---|
| Ticker | AMLX |
| Company Name | Amylyx Pharmaceuticals Inc |
| Country | USA |
| Description | Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company focused on developing groundbreaking therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship candidate, AMX0035, employs a unique neuroprotective mechanism that has shown potential in improving patient outcomes in ALS. With a robust clinical development pipeline and a team of experts in neurological disorders, Amylyx is well-positioned to tackle significant unmet medical needs, making it an attractive investment opportunity for institutional investors seeking exposure to advancements in therapeutic solutions for complex neurological conditions. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 13.29 |
| Price 4 Years Ago | 36.95 |
| Last Day Price Updated | 6/3/2026 11:55:31 AM EST |
| Last Day Volume | 1,650,922 |
| Average Daily Volume | 1,031,752 |
| 52-Week High | 18.61 |
| 52-Week Low | 4.76 |
| Last Price to 52 Week Low | 179.20% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 41.02 |
| Sector PE | 58.19 |
| 5-Year Average PE | -7.34 |
| Free Cash Flow Ratio | 6.45 |
| Industry Free Cash Flow Ratio | 9.71 |
| Sector Free Cash Flow Ratio | 25.14 |
| Current Ratio Most Recent Quarter | 17.85 |
| Total Cash Per Share | 2.06 |
| Book Value Per Share Most Recent Quarter | 2.46 |
| Price to Book Ratio | 5.84 |
| Industry Price to Book Ratio | 14.67 |
| Sector Price to Book Ratio | 8.28 |
| Price to Sales Ratio Twelve Trailing Months | 0.66 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.76 |
| Sector Price to Sales Ratio Twelve Trailing Months | 9.46 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 111,186,000 |
| Market Capitalization | 1,477,661,940 |
| Institutional Ownership | 105.09% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 52.03% |
| Reported EPS 12 Trailing Months | -1.48 |
| Reported EPS Past Year | -0.37 |
| Reported EPS Prior Year | -1.55 |
| Net Income Twelve Trailing Months | -150,112,000 |
| Net Income Past Year | -144,735,000 |
| Net Income Prior Year | -301,743,000 |
| Quarterly Revenue Growth YOY | -99.60% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 229,136,000 |
| Total Cash Past Year | 226,651,000 |
| Total Cash Prior Year | 77,391,000 |
| Net Cash Position Most Recent Quarter | 229,136,000 |
| Net Cash Position Past Year | 225,226,000 |
| Long Term Debt Past Year | 1,425,000 |
| Long Term Debt Prior Year | 1,425,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 305,259,000 |
| Total Stockholder Equity Prior Year | 164,765,000 |
| Total Stockholder Equity Most Recent Quarter | 273,161,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -120,528,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.08 |
| Free Cash Flow Past Year | -123,481,000 |
| Free Cash Flow Prior Year | -167,804,000 |
Options |
|
| Put/Call Ratio | 1.56 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 10.93 |
| 20-Day Bollinger Middle Band | 14.42 |
| 20-Day Bollinger Upper Band | 17.91 |
| Beta | -0.10 |
| RSI | 56.63 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 15.06 |
System |
|
| Modified | 6/2/2026 5:11:53 PM EST |